Effectdossier · gearchiveerd kwartaal
SPRY
ARS Pharmaceuticals, Inc. · Healthcare · Biotechnology
13Gevolgde houders
-4Δ houders
17.49MGehouden aandelen
$175.83MGerapporteerde waarde
+1Nieuwe posities
−5Uitstappen
Momentum-inputs (vergelijkbare managers):
breedte van houders -23.5% ·
aandelenstroom -18.0% ·
netto nieuwe posities -20.0%
— formule
Brede distributie — dalende aandelen en minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +1 | 32.54M | $260.86M | +8 | −7 |
| Q1 2026 | 76 | +2 | 39.92M | $320.66M | +9 | −7 |
| Q4 2025 | 74 | +1 | 37.60M | $438.08M | +2 | −1 |
| Q3 2025 | 13 | -4 | 17.49M | $175.83M | +1 | −5 |
| Q2 2025 | 14 | 0 | 19.24M | $335.74M | +1 | −1 |
| Q1 2025 | 11 | +2 | 5.28M | $66.41M | +2 | — |
| Q4 2024 | 9 | -2 | 6.14M | $64.82M | — | −2 |
| Q3 2024 | 10 | +2 | 3.52M | $51.10M | +3 | −1 |
| Q2 2024 | 8 | — | 1.67M | $14.24M | — | — |
Wie het bezit · Q3 2025
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | BlackRock ✦ (passief) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passief) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passief) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passief) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | The Vanguard Group ✦ (passief) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | The Vanguard Group ✦ (passief) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passief) | 2.90M | +31.9% | $29.10M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 1.59M | -29.3% | $15.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 1.59M | -29.3% | $15.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Geode Capital Management ✦ (passief) | 1.51M | +12.2% | $15.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Geode Capital Management ✦ (passief) | 1.51M | +12.2% | $15.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 22 | Goldman Sachs Group ✦ | 1.33M | — | $13.32M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Goldman Sachs Group ✦ | 1.33M | — | $13.32M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Fidelity (FMR) ✦ | 742.51K | -52.6% | $7.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 25 | Fidelity (FMR) ✦ | 742.51K | -52.6% | $7.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 26 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | Marshall Wace ✦ | 197.32K | +394.4% | $1.98M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 33 | Marshall Wace ✦ | 197.32K | +394.4% | $1.98M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 34 | Marshall Wace ✦ | 197.32K | +394.4% | $1.98M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 35 | Two Sigma Investments ✦ | 72.18K | Nieuw | $725,379 | 0.0% | New | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 37 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 38 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 39 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 40 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 41 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 42 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 43 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 44 | D. E. Shaw & Co. ✦ | 34.22K | -40.4% | $343,901 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 45 | D. E. Shaw & Co. ✦ | 34.22K | -40.4% | $343,901 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 46 | T. Rowe Price ✦ | 33.79K | +23.4% | $340,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Two Sigma Investments | $725,379 | 0.0% |
Verlaten
| Adage Capital Partners | $30.15M | was 0.1% |
| Wellington Management | $25.01M | was 0.0% |
| Millennium Management | $15.32M | was 0.0% |
| Gotham Asset Management | $475,617 | was 0.0% |
| AQR Capital Management | $281,503 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 201 houders, 92.94M aandelen, $730.00M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q3 2025 ·
Methodologie ·
Verkrijg dit via de API